DDInter557 DDInter1588
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} (Compound) resembles {v} (Compound) Ergometrine
Ergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Ribociclib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib